Axitinib is an Ideal Choice in Refractory Renal Cell Carcinoma

Brian I. Rini, M.D., Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Center presents Axitinib is an Ideal Choice in Refractory Renal Cell Carcinoma.